Boston Partners Takes Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Boston Partners purchased a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 426,636 shares of the company’s stock, valued at approximately $15,778,000.

A number of other large investors also recently bought and sold shares of AMPH. Aurora Investment Counsel grew its holdings in Amphastar Pharmaceuticals by 0.4% in the third quarter. Aurora Investment Counsel now owns 54,698 shares of the company’s stock worth $2,654,000 after purchasing an additional 232 shares during the period. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Amphastar Pharmaceuticals by 53.4% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after acquiring an additional 398 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Amphastar Pharmaceuticals by 222.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock valued at $26,000 after acquiring an additional 493 shares in the last quarter. KBC Group NV boosted its stake in Amphastar Pharmaceuticals by 43.1% in the 4th quarter. KBC Group NV now owns 2,159 shares of the company’s stock worth $80,000 after purchasing an additional 650 shares in the last quarter. Finally, Sanctuary Advisors LLC grew its position in Amphastar Pharmaceuticals by 8.5% during the 3rd quarter. Sanctuary Advisors LLC now owns 10,240 shares of the company’s stock valued at $466,000 after purchasing an additional 801 shares during the last quarter. 65.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on AMPH shares. Piper Sandler cut shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $66.00 to $36.00 in a report on Tuesday, February 4th. Wells Fargo & Company assumed coverage on Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price objective on the stock.

Insider Activity

In related news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the sale, the chief financial officer now owns 97,363 shares of the company’s stock, valued at $2,681,377.02. The trade was a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 27.10% of the stock is owned by corporate insiders.

Amphastar Pharmaceuticals Price Performance

AMPH opened at $27.91 on Friday. The company’s 50-day simple moving average is $32.07 and its two-hundred day simple moving average is $40.71. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The stock has a market capitalization of $1.33 billion, a P/E ratio of 9.30, a P/E/G ratio of 2.19 and a beta of 0.77. Amphastar Pharmaceuticals, Inc. has a 52-week low of $25.89 and a 52-week high of $53.96.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.